Review

IAEA Contribution to Nanosized Targeted Radiopharmaceuticals for Drug Delivery

Amir R. Jalilian 1, Blanca Ocampo-Garcia 2, Wanvimol Pasanphan 3, Tamer M. Sakr 4, Laura Melendez-Alafort 5, Mariano Grasselli 6, Ademar B. Lugao 7, Hassan Yousefnia 8, Clelia Dispenza 9, Siti Mohd Janib 10, Irfan U. Khan 11, Michal Maurin 12, Piotr Ulański 13, Say Chey Joachim Loo 14, Agnes Safrany 1, Joao A. Osso, Jr. 1, Adriano Duatti 15 and Kattesh V. Katti 16.*

1 Department of Nuclear Sciences and Applications, International Atomic Energy Agency (IAEA), 1400 Vienna, Austria; a.jalilian@iaea.org (A.R.J.); a.safrany@iaea.org (A.S.); j.a.osso-junior@iaea.org (J.A.O.J.)
2 Departamento de Materiales Radiactivos, Instituto Nacional de Investigaciones Nucleares, Ocoyoacac 52750, Mexico; blanca.ocampo@nin.gov.mx
3 Department of Materials Science, Faculty of Science, Kasetsart University, Bangkok 10900, Thailand; fsiwvm@ku.ac.th
4 Radioactive Isotopes and Generators Department, Hot Labs Center, Egyptian Atomic Energy Authority (EAEA), Cairo 13759, Egypt; tamer_sakr78@yahoo.com
5 Istituto Oncologico Veneto IOV-IRCCS, Via Gattamelata 64, 35138 Padova, Italy; laura.melendezalafort@iov.veneto.it
6 Laboratorio de Materiales Biotecnológicos (LaMaBio), Dpto de Ciencia y Tecnología, Universidad Nacional de Quilmes, Bernal 1876, Argentina; mariano.grasselli@unq.edu.ar
7 Instituto de Pesquisas Energéticas e Nucleares, IPEN-CNEN, Av. Prof. Lineu Prestes, No. 2242, Cidade Universitária, São Paulo 05080-000, SP, Brazil; ablugao@gmail.com
8 Nuclear Science and Technology Research Institute (NSTRI), Tehran 11155-3486, Iran; hyousefnia@aeoi.org.ir
9 Dipartimento di Ingegneria, Università deli Studi di Palermo, 90133 Palermo, Italy; clelia.dispenza@unipa.it
10 Medical Technology Division, Malaysian Nuclear Agency, Kajang 43000, Malaysia; najila@nuclearmalaysia.gov.my
11 Cyclotron and Allied Radiopharmaceuticals Division, Institute of Nuclear Medicine and Oncology (INMOL), New Campus Road, Lahore 54600, Pakistan; drrifankhan69@gmail.com
12 National Centre for Nuclear Research, Radioisotope Centre POLATOM, 05-400 Otowek, Poland; m.maurin@polatom.pl
13 Institute of Applied Radiation Chemistry, Lodz University of Technology, 90-924 Łódz, Poland; ulanskip@mifr.plodz.pl
14 School of Materials Science & Engineering (MSE), Spore Centre of Environmental Life Sciences Engineering (SCELSE), Lee Kong Chian School of Medicine, Harvard T.H. Chan School of Public Health, Nanyang Technological University (NTU), Singapore 639798, Singapore; joachimloo@ntu.edu.sg
15 Department of Chemical and Pharmaceutical Sciences, University of Ferrara, 44121 Ferrara, Italy; dt@unife.it
16 Department of Radiology, Institute of Green Nanotechnology, School of Medicine, University of Missouri, University of Missouri Research Reactor (MURR), Medical School, One Hospital Drive, Columbia, MO 65212, USA

* Correspondence: kattik@health.missouri.edu; Tel.: +1-573-882-5656

Abstract: The rapidly growing interest in the application of nanoscience in the future design of radiopharmaceuticals and the development of nanosized radiopharmaceuticals in the late 2000’s, resulted in the creation of a Coordinated Research Project (CRP) by the International Atomic Energy Agency (IAEA) in 2014. This CRP entitled ‘Nanosized delivery systems for radiopharmaceuticals’ involved a team of expert scientist from various member states. This team of scientists worked on a number of cutting-edge areas of nanoscience with a focus on developing well-defined, highly effective and site-specific delivery systems of radiopharmaceuticals. Specifically, focus areas of various teams of scientists comprised of the development of nanoparticles (NPs) based on metals, polymers, and gels, and their conjugation/encapsulation or decoration with various tumor avid ligands such as peptides, folates, and small molecule phytochemicals. The research and development efforts also comprised of developing optimum radiolabeling methods of various nano vectors using diagnostic and therapeutic radionuclides including Tc-99m, Ga-68, Lu-177 and Au-198. Concerted efforts of teams of scientists within this CRP has resulted in the development of various protocols and guidelines on delivery systems of nanoradiopharmaceuticals, training of numerous graduate students/post-doctoral fellows.
and publications in peer reviewed journals while establishing numerous productive scientific networks in various participating member states. Some of the innovative nanoconstructs were chosen for further preclinical applications—all aimed at ultimate clinical translation for treating human cancer patients. This review article summarizes outcomes of this major international scientific endeavor.

**Keywords:** nanoparticles; metallic; non-metallic; polymeric; radiopharmaceuticals; radioisotopes; nanogels; theranostic; drug delivery; nanoradiopharmaceuticals

### 1. Introduction

The versatile surface chemistry of biocompatible nanomaterials has allowed the development of innovative nanodrug delivery systems for use in molecular imaging and therapy of various diseases. For example, the surface chemistry of gold nanoparticles (AuNPs) allow for efficient loading of DNA or RNA onto the surfaces via strong and biocompatible covalent interactions [1,2]. Tumor specific targeting abilities of cancer drug functionalized nanomedicine agents are proving to be highly effective in alleviating debilitating effects of adverse toxicity and drug resistance of standard FDA approved cancer therapy agents [3–9]. Several recent investigations have shown compelling scientific evidence that nanosizing of pharmaceuticals results in reducing onset of cancer drug resistance, and site specificity reduces systemic drug toxicity, offering significant improvement in therapeutic efficacy of current and future chemotherapeutic agents [6–11]. In sharp contrast to recent successes of nanosizing various pharmaceutical agents, currently used radiotherapeutic agents in nuclear medicine continue to pose medical challenges mainly due to the limited uptake of diagnostic/therapeutic radioprobes within tumor sites [12]. Problems associated with effective delivery of nuclear medicine radiotherapeutic drugs pose severe oncological challenges, especially when treating solid tumors (sarcomas, carcinomas, and lymphomas) which account for over 85% of all human cancers. Circumventing these problems is not easy because molecular and cellular biology of neoplastic cells alone fails to explain the non-uniform uptake of these agents in solid tumors. Repeated delivery of radiopharmaceuticals is not an option due to long lasting systemic radiotoxicity, creating major collateral adverse effects where cancer cells mutate, making them resistant to radiation therapy, chemotherapy and other treatments. Specifically, various beta-emitting therapeutic nuclear medicine agents have failed to deliver optimum therapeutic payloads at tumor sites. Therefore, the discovery of new classes of radiopharmaceutical drug delivery approaches that effectively penetrate extracellular compartments, consisting of vascular and interstitial valves within solid tumors, is of profound importance.

I-131 shows remarkably high tumor accumulation compared to any other radionuclide for diagnosis or therapy. I-131 is a widely accepted theranostic nuclear medicine agent extensively used to aid diagnosis and treatment especially for pre- and post-therapy scans in differentiated thyroid cancer patients [13]. This approach provides accurate surveillance of the disease—thus guiding clinicians for the treatment [13]. It is important to recognize that the high and specific uptake of diagnostic/therapeutic I-131 agent in tumors is a rarity because I-131 agents and a vast majority of nuclear medicine agents fail to localize in optimum doses in neo vascular lesions. This means that metastases of several different types of aggressive cancers cannot be detected accurately or treated through currently available nuclear medicine agents—thus resulting in the propagation of cancers to various other organs including—ultimately resulting in death in cancer patients’ population. Therefore, there is an overarching urgent need in the creation of new radiotherapeutic delivery modalities that offer: (i) effective delivery of radiotherapeutic probes with optimum payloads—specifically at tumor sites—with minimal/tolerable systemic toxicity, and (ii) therapeutically optimum tumor retention. Such innovative approaches would bring about a clinically measurable shift in the way cancers are diagnosed and treated. Nanotechnology has the potential to bring about this paradigm shift in the early detection and therapy of various forms
of human cancers because radioactive NPs, of optimum sizes and conjugated to tumor specific targeting vectors, can be engineered to achieve effective penetration across tumor cell membranes. The disruptive and interdisciplinary nature of the field of nanotechnology is attracting the attention of a myriad of interdisciplinary professional teams of experts from nuclear medicine, materials sciences, physics, chemistry, tumor biology and oncologists engaged in testing the efficacy of nanosized radiopharmaceuticals in pursuits of achieving optimum diagnostic or therapeutic payloads of nuclear medicine agents.

Radiolabeled tumor specific, peptide-conjugated nanopharmaceuticals can be engineered in sizes that would allow effective and site-specific accumulation of diagnostic or therapeutic probes in tumor cells/lesions through dual receptor specific endocytosis, as well as through passive enhanced permeation and retention (EPR) effects. In order to validate the hypothesis that nanosized radiopharmaceuticals provide the best means to achieve optimum accumulation and site, specifically of radioactive diagnostic/therapeutic probes in tumor sites, the IAEA launched an innovative Coordinated Research Project (CRP) entitled ‘Nanosized delivery systems for radiopharmaceuticals’ in 2014. The overarching objective of this CRP centered around the development of radiolabeled nanomedicine agents for diagnosis, therapy and theranostics of human cancers. As an international platform for peaceful applications of nuclear science and technology, the IAEA promotes and supports member states in various ways, including various international research projects, such as this CRP. The research, development, and collaborative activities of interdisciplinary scientists from 15 member countries participating in the CRP (Figure 1) focused on the development of new radiolabelled polymeric/hydrogel NPs, and also the radioactive Au-198-based nanoceuticals. This CRP is highly relevant for cancer diagnosis and treatment because targeted radiolabelled NPs would be ideal for homing in and penetrating tumor vasculature to provide optimum therapeutic/diagnostic payloads to solid tumors. Such an approach has the potential to minimize/stop metastases because once the primary tumors are destroyed, the tumor specific NPs would stop the recruitment of proliferating tumor cells into the bone marrow. This review is a culmination of innovative research findings of the international team of researchers who worked collaboratively under the auspices of IAEA’s CRP (Figures 1 and 2).

![Figure 1. International distribution of the project participants from the member states.](image-url)
2. Radionuclides for Radiolabeling Various Nanoparticles

Labeled NPs conjugated to specific biomolecules belong to an innovative class of diagnostic or theranostic radiopharmaceuticals. A nanoradiopharmaceutical is a multimeric compound comprising a nanoparticulate system, a radionuclide (including radioactive NPs) and a targeting molecule. Their potential applications are numerous, including targeted radioactive drug delivery systems for radiotherapy, as well as diagnostic imaging agents—all in a single nanoplatform.

To design a new nanoradiopharmaceutical, it is important to select the most appropriate radionuclide with an emission type ($\alpha$, $\beta^-$, $\beta^+$ or $\gamma$) that will confer appropriate characteristics of diagnostic, therapeutic or theranostic payloads. The most important properties to consider when selecting a suitable radionuclide are the emission mode, half-life, chemical properties, ease of production and availability of target pre-irradiation materials. Table 1 summarizes various radionuclides used in the architecture of nanoradiopharmaceuticals discussed in this review. The radiolabelling can be carried out by mainly two methods: (i) through creation of covalent bonds between radionuclide(s) and targeting vectors, or (ii) through a bifunctional chelating agent approach such as DOTA, HYNIC [14]. Generally, radiolabeling strategies, using a bifunctional chelating agent, are preferred due to their higher in vivo stability—thus resulting in higher tumor specificity.

$^{99m}$Tc is a radionuclide, which has been most widely used to label tumor specific biomolecules, that presents tremendous potential for labelling NPs for developing SPECT imaging agents. Its gamma-emission has ideal properties for single photon emission computed tomography (SPECT) and would be ideal for development of diagnostic nanoradio-
This radionuclide has been used extensively in nuclear medicine for the development of target-specific molecular imaging of alpha(v)beta(3) integrins, somatostatin receptors, gastrin releasing peptide receptors (GRPr), for sentinel node detection and a myriad of receptor positive tumors [15–20], as well as in imaging of cancers that overexpress Scavenger Receptor type B1 [21]. 99mTc is also useful to follow the doxorubicin delivery from 99mTc-DOX-loaded GA-Au NPs [22] and 99mTc-Doxorubicin-Epigallocatechin gallate functionalized gold nanoparticles [23]. In addition, 99mTc can also be considered a theranostic radionuclide if its Auger electrons are emitted within the cell nucleus because, despite the low energy of its Auger electrons, they can be deposited in a very small area. Consequently, if Auger electrons are emitted close to the DNA, their biological effects might mimic that of α particles, causing inhibition of cell proliferation or even cell death [24,25]. In this review, we confine discussions of nanoradiopharmaceutical to those developed through the IAEA CRP, which includes 99mTc, but also 68Ga and 198Au, and allied diagnostic and therapeutic radioisotopes (see Table 1).

Radionuclides including 67Cu, 131I, 153Sm, 177Lu, 188Re and 198Au that decay emitting a combination of β− particles are suitable for therapy, and those that emit γ-rays are useful for SPECT imaging. 177Lu is one of the most widely used radionuclides for labeling radiopharmaceuticals due to its attractive decay properties. This radionuclide has a relatively long half-life (6.65 d) and emits a combination of β− particles with Emax = 0.497 MeV (76%) and low-energy gamma photons Ey = 113 keV (6.6%) and 208 keV (11%) [26]. Furthermore, 177Lu can form very stable complexes with several commercially available chelating agents including DOTA derivatives. Therefore, this radionuclide has been used to radiolabel several target-specific nanopharmaceuticals for therapeutic purposes [22,27,28], as well as for combinatorial oncotherapeutic drug delivery and targeted radiotherapy [29–31]. This approach has resulted in synergic effects between targeted radiotherapy and plasmonic photothermal therapy [32,33].

Nanoparticles intrinsically labeled using radionuclides such as 64Cu, 72As, 111In, 153Sm, 177Lu and 198Au, without employing chelators, have also been reported [34–37]. 198Au emits a beta energy (0.96 MeV) ideal to penetrate within the tumor tissue up to 11 mm, providing cross-fire effects which can destroy the tumor cells [38]. Therefore, several 198Au-gold nanoparticles (198AuNPs) were developed in the framework of this project (see Table 1). 198AuNPs stabilized with epigallocatechin gallate (EGCG) and mangiferin (MGF) phytochemicals are some examples of nanoradiopharmaceuticals successfully translated to the clinical practice [38]. An attractive feature is that tumor specific 198AuNPs can be architected through green nanotechnology approaches by direct irradiation of natural gold foil or metal Au-197 (n, γ) for breast and prostate cancer therapy (see Section 5 for details) [38–42].

### Table 1. Radioisotopes for labelling various nanoradiopharmaceuticals.

| Radionuclide | Half-Life | Decay Mode (Energy, Intensity) | Applications | Type of Nanoparticle | Ref. |
|--------------|-----------|-------------------------------|--------------|----------------------|-----|
| Ga-68        | 67.7 m    | β+ (1.89 MeV, 88%)            | PET imaging  | 68Ga-DOTA-BN-TMC-MNPs [43] |
| Tc-99m       | 6 h       | γ-ray (140 keV)               | SPECT imaging| 99mTc-AuNPs          | [44,45] |
|              |           |                               |              | 99mTc-AuNP-Tyr3-Octreotide [17,46] |
|              |           |                               |              | 99mTc-DOX-AuNPs [22,47] |
|              |           |                               |              | 99mTc-ACuONPs [48] |
|              |           |                               |              | 99mTc-SeNPs [49] |
|              |           |                               |              | 99mTc-VitC-SeNPs [50] |
|              |           |                               |              | 99mTc-MIONPs [51] |
| I-131        | 8 d       | β− (606 keV, 90%)             | Therapy and  | 131I-doped Ag-PEG NPs [52] |
|              |           | γ-ray (364 keV, 81%)          | SPECT imaging|                      |

In addition, 99mTc can also be considered a theranostic radionuclide if its Auger electrons are emitted within the cell nucleus because, despite the low energy of its Auger electrons, they can be deposited in a very small area. Consequently, if Auger electrons are emitted close to the DNA, their biological effects might mimic that of α particles, causing inhibition of cell proliferation or even cell death [24,25]. In this review, we confine discussions of nanoradiopharmaceutical to those developed through the IAEA CRP, which includes 99mTc, but also 68Ga and 198Au, and allied diagnostic and therapeutic radioisotopes (see Table 1).
Table 1. Cont.

| Radionuclide | Half-Life | Decay Mode (Energy, Intensity) | Applications | Type of Nanoparticle | Ref. |
|--------------|-----------|-------------------------------|--------------|----------------------|-----|
| Sm-153       | 46.3 h    | $\beta^-$ (634 keV, 30%, 704 keV, 49% and 807 keV, 20%) γ-ray (103 keV, 29%) | Therapy | $^{153}$Sm-CSNPs-PEI-folate | [53] |
| Lu-177       | 6.6 d     | $\beta^-$ (496 keV, 80%) γ-ray (113 keV, 6% and 208 keV, 10%) | Theranostic | $^{177}$Lu-DOTA-DN(PTX)-BN | [29] |
|              |           |                               |              | $^{177}$Lu-BN-PLGA(PTX) | [26] |
|              |           |                               |              | $^{177}$Lu-DOTA-HA-PLGA(MTX) | [54] |
|              |           |                               |              | $^{177}$Lu-DN(AuNP)-folate-BN | [55] |
|              |           |                               |              | $^{177}$Lu-DN(C19)-CXCR4 | [31,56] |
| Au-198       | 2.7 d     | $\beta^-$ (961 keV, 99%) γ-ray (411 keV, 96%) | Therapy | $^{198}$AuNPs | [57] |
|              |           |                               |              | $^{198}$AuNPs-BSA | [58] |
|              |           |                               |              | MGF-$^{198}$AuNPs | [38,42] |
|              |           |                               |              | AX-encapsulated $^{198}$AuNPs | [59] |
| Au-199       | 3.1 d     | $\beta^-$ (243 keV, 22% and 293 keV, 72%) γ-ray (158 keV, 40%) | Therapy | $^{199}$AuNPs | [57] |

3. Design and Development of Nanoparticles

Due to unprecedented diagnostic/therapeutic multiplexing capabilities, functionalized NPs have the potential to play a key role in delivering various radionuclides for nuclear imaging and therapy. By tailoring the properties of NPs, such as chemical composition, size, shape and surface properties, including tumor site-specific targeting molecules, NPs can be rationally designed down to the single-molecular level to achieve desirable properties. Such properties include nanoparticulate stability, optimal pharmacokinetics, tissue penetration, cell internalization, and targeting efficacy. Inorganic metals and polymers have served as important building blocks for constructing NPs as drug delivery systems. In addition, hybrid NPs comprising both metal and polymeric components have also been considered for nanosized delivery because of the combined benefits of co-delivery of both diagnostic and therapeutic agents. Figure 3 illustrates NPs developed from inorganic metals and polymers using chemical-based and radiation-based synthesis under this IAEA CRP. By tailoring molecular structures using suitable synthetically designed methods, nanoparticles with a myriad of nanostructures including inorganic NPs, hybrid NPs, dendrimer/multibranched structures, nanogels from both synthetic and biopolymers, amphiphilic or core-shell NPs from graft copolymer and functional polymers, can be developed for use in radiopharmaceuticals delivery.

Chemical-Based Synthesis of Nanoparticles—General Aspects of Production

Formation of chemical-induced metallic NPs are usually based on conventional chemical reduction and phytochemical-induced reduction mechanisms. For polymeric NPs, polymerization, copolymerization, graft copolymerization, crosslinking and chemical functionalization are used for tailoring polymeric structures for the creation of NPs under appropriate conditions. Selected NPs from chemical-based synthesis are listed in Table 2, along with their size and summary of synthesis.
Figure 3. Structurally-controlled NPs developed through chemical- and radiation-based techniques for use in the creation of nanoradiopharmaceutical delivery approaches.

Table 2. List of functionalized nanoparticles developed through chemical-based synthesis.

| Categories of NPs | Name of NPs | Size (nm) | Information of NPs | Ref. |
|-------------------|-------------|-----------|--------------------|------|
| Inorganic         | AgNP        | 21        | AgNP prepared using ascorbic acid reducing agent and polyethylene glycol stabilizing agent for delivering $^{131}$I radioisotope. | [52] |
|                   | SeNP        | 43        | SeNP prepared using sodium dithionate reducing agent and glutathione stabilizing agent for $^{99m}$Tc. | [49] |
|                   | SeNP        | 23        | SeNP prepared using sodium dithionate reducing agent and ascorbic acid as stabilizing agent for delivering $^{99m}$Tc radioisotope. | [50] |
|                   | AuNP        | 30–85     | AuNP prepared using mangiferin as reducing and stabilizing agents for delivering $^{198}$Au radioisotope. | [42] |
|                   | AuNP        | 20.3      | AuNP prepared using Trisodium citrate as reducing and stabilizing agents for delivering $^{99m}$Tc radioisotope. | [44,47] |
|                   | AuNP        | 50        | AuNP prepared using gallic acid as reducing and stabilizing agent for delivering $^{99m}$Tc radioisotope. | [22,45,60] |
|                   | Fe oxide NP | 24        | Fe oxide NPs prepared by co-precipitation method and using polyethylene glycol as stabilizing agent for delivering $^{99m}$Tc radioisotope. | [51] |
### Table 2. Cont.

| Categories of NPs | Name of NPs | Size (nm) | Information of NPs | Ref. |
|-------------------|-------------|-----------|--------------------|------|
| **Cu oxide NP**   | 32.4        | Cu oxide NPs prepared by biological synthesis using *Aspergillus flavus* for delivering $^{99m}$Tc. | [48] |
| **Polymers**      | $^{99m}$Tc-PAMAM-Tyr${}^{3}$-Octreotide $^{99m}$Tc -AuNP-Tyr${}^{3}$-Octreotide. | 20 $^b$ | Dendrimer-based or gold-based nanoradiopharmaceuticals for somatostatin receptors imaging on neuroendocrine tumors. | [17,46] |
|                   | 177Lu-DenAuNP-folate-bombesin | 18.60 ± 8.00 $^b$ | $^{177}$Lu-dendrimer (PAMAM-G4)-folate-bombesin with AuNPs in the dendritic cavity for targeted radiotherapy and the simultaneous detection of folate receptors (FRs) and gastrin-releasing peptide receptors (GRPRs) overexpressed in breast cancer cells. | [46,55,56] |
|                   | DOX-PLGA/γ-PGA-FA | 597 ± 45.0 $^a$ | Poly(L-γ-glutamic acid) (γ-PGA) conjugated to modified folic acid (FA) as a targeting ligand for specific doxorubicin delivery. | [61] |
|                   | PMAA(PTX)-RGD | 17.5 ± 7.4 $^b$ | Multimeric system of RGD-grafted PMMA- nanoparticles as a targeted drug-delivery system for paclitaxel. | [62] |
|                   | 177Lu-PLGA(PTX)-BN | 163.54 ± 33.25 $^a$ | A targeted paclitaxel delivery system with concomitant radiotherapeutic effect for the treatment of GRPr-positive breast cancer. | [30] |
|                   | 177Lu-DOTA-HA-PLGA(MTX) | 167.6 ± 57.4 $^a$ | Multifunctional chemo/radiotherapy agent based on PLGA, modified with hyaluronic acid and DOTA as a chelating agent for radiosynovectomy and specific targeted anti-rheumatic therapy. | [54] |
|                   | 177Lu-DOTA-DN(PTX)-BN | 16.37 $^a$ | Bombesin targeted polymeric NPs designed to produce radiotherapy and chemotherapy towards GRP receptors. | [29,55] |
|                   | 177Lu-DN(C19)-CXCR4 | 67.0 ± 23.17 $^a$ | Nanoradiopharmaceutical dendrimer-based for combinatorial therapy (targeted chemotherapy and radiotherapy) in pancreatic cancer cell lines overexpressing the CXCR4 receptor. | [31] |

$^a$ Hydrodynamic size, $^b$ Size determined by TEM, $^c$ Size determined by AFM.

Inorganic NPs include metallic NPs, metal oxide nanoparticles, magnetic NPs, and quantum dots [63–66]. Inorganic NPs can be chemically synthesized using several different techniques such as co-precipitation, hydrothermal, combustion, sol-gel, chemical reduction, chemical vapor and microwave-assisted methods [67–71]. In this review, we present inorganic NPs that are synthesized using reducing and stabilizing agents where the reducing agent is responsible for the reduction of the metal from high oxidation states (+3, +2 or +1) to its metallic form (zero oxidation state), while the stabilizing agent is responsible for surface stabilization of metal nano materials [22,42,44,45,47,49,50,52]. Various NPs including AuNPs, selenium nanoparticles (SeNP), iron nanoparticles (FeNP), copper nanoparticles (CuNP) and silver nanoparticles (AgNP) were evaluated for their effective
delivery of different radionuclides such as tecnecium-99m (Tc-99m), iodine-131 (I-131) and gold-198 (Au-198) to tumor sites for tumor theranostics [42,44,45,47–52,72].

Multimeric systems based on polymeric NPs have also been designed, synthesized, characterized and evaluated for targeted combinatorial radiotherapy and chemotherapy. These type of nanoradiopharmaceuticals can deliver therapeutic radiation doses including specific drugs to tumor sites, thus reducing collateral damage to healthy tissue. Under this CRP, several radiolabelled nanoprobe have been studied as promising radiopharmaceuticals for targeted chemo/radiotheranostic applications. In this context, specific nanoradiopharmaceuticals based on dendrimers and PLGA have been conjugated to targeting biomolecules such as CXCR4L [31], bombesin [29,30], RGD peptide [62] and folic acid [61] to specifically target tumors which over-express tumor specific receptors. Hyaluronic acid was conjugated to PAMAM dendrimers to target CD44 receptors on activated macrophages in rheumatoid arthritis [54]. DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10 tetraacetic acid) has been used as a bifunctional chelator for a Lu-177 beta-emitter.

4. Radiation-Based Synthesis of Nanoparticles

A radiation-induced chemical reactions approach is one of the effective and green processes well-suited for the development of biomedical nanomaterials. This approach presents excellent opportunities for tailoring varieties of nanostructured morphologies of inorganic materials and polymers. This technique is versatile due to its simplicity and fast reaction kinetics/operations, and is catalyst free. Radiation-induced chemical reactions enjoy additional unique advantages as they employ powerful radiolysis for controlling chemical reactions, which also simultaneously provides sterilization processes. Radiation-based synthesis for NPs construction can be carried out through degradation, crosslinking, graft copolymerization, and also radiation-induced reduction of metallic ions. This technique can be used for generating (i) radiation-crosslinked nanogels from synthetic/biopolymers [73–84], (ii) conjugated NPs from size-controlled polymer templates through radiation [85,86], (iii) NPs from self-assembly of radiation-induced grafted copolymers [87,88], and (iv) AuNPs-hybrid NPs from radiation-induced reduction [89–94]. These are summarized in Table 3. For example, the crosslinked poly(acrylic acid) (PAA) nanogels prepared from pulse radiolysis has been studied through careful control of particle sizes by absorbed dose and dose rate [73–75,95]. The interpolymer-complex (IPC) nanogels composed of two polymer components is also a promising multifunctional-designed nanostructure [76].

Radiation-crosslinking techniques have also been applied for synthesis of IPC nanogels from polyethylene oxide-PAA (PEO-PAA) systems, with pH- and temperature-responsive functions [76] as smart nanocarrier approaches. With the carboxylic groups (−COOH) of PAA and responsive functions, controlled delivery of radiopharmaceuticals and tumor target specific peptide conjugates are possible. Grafting polyvinyl pyrrolidone (PVP)-based nanogels and conjugating with functional molecules, such as acrylic acid, folic acid, amino-terminated groups, (3-N-aminopropyl) methacrylamide hydrochloride, insulin, and monoclonal antibody, was applied to develop functional and selective nanocarriers [82–84,96–100]. In addition, the synthetic polymeric nanogels, radiation-induced crosslinking of protein-based NPs was studied under controlled and varying irradiation conditions. An albumin nanogel was successfully established for applications as therapeutic drug carriers [77–81].

Particle size of NPs can be controlled using polymer chain templates. Radiation-controlled polymer-chain templates for controlling particle size of deoxycholic acid functionalized chitosan NPs as a drug nanocarrier was demonstrated [85,86]. Radiation-induced graft copolymerization of stearyl methacrylate (pSMA) or poly(poly(ethylene glycol) monomethacrylate) (pPEGMA), as hydrophobic/hydrophilic polymer brushes on chitosan, have been reported [87,88]. In this way, building blocks of grafted copolymers showed their ability to self-assemble into confined amphipilic core-shell NPs for antibiotic drug encapsulation and antioxidant molecule functionalization. With plenty of functional hydroxyl (−OH) and amino (−NH₂) functional groups on chitosan, chitosan-based NPs
exhibited availability for conjugating with radionuclide-chelating-molecules and targeted peptide biomolecules [91]. Nano-templates of water-soluble biopolymer polysaccharide and polypeptide from radiation-controlled processes were applied for one-pot synthesis of AuNPs [89–91,101]. Recently ready-to-use templates for radioactive $^{198}$AuNPs, using biopolymers incorporating tumour-targeted peptides, have been successfully developed for use as nanomedicine agents in molecular imaging and therapy [91]. It has been proven that core-shell AuNPs can be efficiently synthesized in albumin protein solution under irradiation [92,93,95].

Radiation-based synthesis of NPs allow systematic variations in functions and properties of NPs for nanoradiopharmaceutical applications. Under the controlled-synthesis process (e.g., absorbed dose, dose rate, polymer characteristics, polymer-size template, and grafted monomer), the particles sizes of the confined nanostructures can be controlled. The particle sizes of metallic/hybrid NPs and polymeric NPs generated were found in the ranges of 5–100 nm and 20–300 nm, respectively. With their specific characteristics and functionalities, these NPs provide prospects for drug encapsulation and, as radioisotope carriers, for tumour-targeting through theranostic modes.

Table 3. List of NPs developed by radiation-based synthesis.

| Categories of NPs | Name of NPs                      | Size (nm) | Information of NPs                                                                                                                                                                                                 | Ref.        |
|-------------------|---------------------------------|-----------|-------------------------------------------------------------------------------------------------------------------------------- Adamantean a NPs developed by radiation-based synthesis. |            |
| Polymeric         | PAA nanogels                    | 30–200 a  | Nanogels of poly(acrylic acid) synthesized by preparative pulse radiolysis and decorated with bombesin/DOTA, tested for radioisotope binding and subjected to preliminary tests on animal model (mice). | [73–75]    |
|                   | PAA-PEO IPC nanogels            | ~100–240 a| Poly(acrylic acid)-poly(ethylene oxide) interpolymer (IPC) complex nanogels exhibiting pH- and temperature-responsive functions and possible for drug-controlled release. | [76]       |
|                   | PVP-g-AA-Folate                 | 20–60 a   | Polyvinyl pyrrolidone based nanogels with acrylic acid grafts: (i) decorated with folic acid (FA) for preferential uptake by cells that overexpress folate receptors; (ii) conjugated, via a redox-cleavable linker, to either doxorubicin or a silencing RNA. | [82–84]    |
|                   | PVP-g-AA-Doxo                   | 20–60 a   | Polyvinyl pyrrolidone-based nanogels with acrylic acid grafts conjugated to the amino-terminated AntimiR-31, that targets MiR-31, a microRNA overexpressed by primary and metastatic tissue colon cancer cells (CCR) and target of the E2F2 gene that plays a crucial role in the control of CCR progression. | [100]      |
|                   | PVP-g-AA-SiRNA                  | ~50 a     | Polyvinyl pyrrolidone-based nanogels with acrylic acid grafts, conjugated to insulin to be intranasally delivered, bypass the blood–brain barrier and target the brain. | [96,97]    |
|                   | PVP-g-AA-Insulinl               | ~80 a     |                                                                                                                                                      |            |
### Table 3. Cont.

| Categories of NPs | Name of NPs          | Size (nm) | Information of NPs                                                                                                                                                                                                 | Ref.       |
|-------------------|----------------------|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|
| Polymeric         | PVP-g-APMAM          | 80–300 a  | Polyvinyl pyrrolidone-based nanogels with (3-N-aminopropyl)methacrylamide hydrochloride grafts, conjugated to a monoclonal antibody which recognizes the αvβ3 integrin, a receptor important in tumor angiogenesis and metastasis. | [98,99]    |
|                   |                      |           |                                                                                                                                                                                                                     |            |
| Protein NPs       |                      | 20–40 a   | Albumin NPs prepared by a novel radiation-induced crosslinking method. Albumin preserve their original drug-carrier properties.                                                                                   | [77–81]    |
|                   |                      |           |                                                                                                                                                                                                                     |            |
| CS-DC NPs         |                      | 50–100 b  | Deoxycholate conjugated chitosan NPs containing hydrophobic core for water-insoluble drug encapsulation. NPs remaining -OH and -NH$_2$ groups for further conjugating with chelating/peptide molecules. | [85,86,91] |
|                   |                      | 30–50 b   |                                                                                                                                                                                                                     |            |
|                   |                      |           | Poly(ethylene glycol) monomethacrylate grafted chitosan deoxycholate amphiphilic NPs containing hydrophobic core for water-insoluble drug encapsulation (e.g., berberine). NPs remaining -OH and -NH$_2$ groups for further conjugating with chelating/peptide molecules. | [87,91]    |
| pPEGMA-CS-DC NPs  |                      | 70–130 b  | Poly(stearyl methacrylate) grafted chitosan NPs providing -OH and -NH$_2$ groups for further conjugating with chelating/peptide molecules.                                                                          | [87,91]    |
|                   |                      |           |                                                                                                                                                                                                                     |            |
| pSMA-CS NPs       |                      | 50–140 b,c| Piperidine conjugate poly(stearylate)-grafted chitosan NPs exhibiting antioxidant function and remaining -OH and -NH$_2$ groups for further conjugating with chelating/peptide molecules.                                   | [87,91,102]|
|                   |                      |           |                                                                                                                                                                                                                     |            |
| pSMA-CS-PPD NPs   |                      | 50–100 b  |                                                                                                                                                                                                                     | [88,91]    |
|                   |                      |           |                                                                                                                                                                                                                     |            |
| WSCS nanocolloids |                      | 49 ± 2.15 a | Water-soluble chitosan nanocolloids exhibiting antioxidant activities and reducing power. NPs remaining -OH and -NH$_2$ groups for conjugating with chelating/peptide molecules. NPs enable use as biopolymer-template synthesis of Au-197 and Au-198 analogue. | [89,91]    |
|                   |                      | 10–50 b   |                                                                                                                                                                                                                     |            |
| SF nanocolloids   |                      | ~40 b     | Silk fibroin (SF) nanocolloids exhibit antioxidant activities and reducing power. NPs enable use as biopolymer-template synthesis of Au-197 and Au-198 analogue.                                                   | [101]      |
|                   |                      |           |                                                                                                                                                                                                                     |            |
| WSCS-DOTA-BBN NPs |                      | 86 ± 2.03 a | Water-soluble chitosan conjugated DOTA NPs chelator and BBN peptide enable use as one-pot synthesis of targeted AuNPs.                                                                                         | [91]       |
Table 3. Cont.

| Categories of NPs   | Name of NPs                      | Size (nm) | Information of NPs                                                                                                                                                                                                 | Ref.     |
|---------------------|----------------------------------|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------|
| Inorganic/hybrid    | AuNPs-CS                         | 5–80 b    | Protocol synthesis of AuNPs capped with chitosan enable use for one-pot synthesis of $^{198}$Au nanoradiotherapeutics.                                                                                               | [89,90]  |
|                     | AuNPs-WSCS                       | 5–25 b    | Protocol synthesis of AuNPs capped with water-soluble chitosan enable use for one-pot synthesis of $^{198}$Au nanoradiotherapeutics.                                                                             | [90]     |
|                     | AuNPs-WSCS-DOTA-BBN              | 62 ± 21 a 20 ± 7 b | AuNPs capped with water-soluble chitosan conjugated DOTA chelator and BBN peptide acting as targeted therapeutic agent for prostate cancer cells (i.e., PC-3, LNCaP). Protocol for a one-pot synthesis of the targeted $^{198}$Au nanoradiotherapeutics. | [91]     |
|                     | AuNPs-WSCS-GA-DOTA-BBN           | 40–60 a   | BBN peptide conjugated water-soluble chitosan gallate as a new nanopharmaceutical architecture for the rapid one-pot synthesis of prostate tumor targeted AuNPs                                                                 | [103]    |
|                     | bioHNPs                          | 77 ± 7 a  | AuNPs coated with human albumin multilayer and further decorated with DOTA chelator and BBN peptide acting as targeted therapeutic agent for prostate cancer cells (i.e., PC-3).                                              | [92–95]  |

a Hydrodynamic size, b Size determined by TEM, c Size determined by AFM.

Our work on mangiferin-conjugated radioactive gold nanoparticles of Au-198 (MGF-$^{198}$AuNPs) represents the most advanced research development because (i) we have optimized the production of Au-198 nanoparticles; (ii) performed extensive in vitro investigations on their stability and also investigated biodistribution in normal mice, and finally (iii) we have also evaluated tumor retention as well as therapeutic efficacy of MGF-$^{198}$AuNPs in tumor bearing mice. Therefore, we have presented full details of preclinical/clinical investigations of this singular nanomedicine agent, as a representative candidate, in this review article.

5. Production, Characterization, and Pre-Clinical/Clinical Investigations of Radioactive MGF-$^{198}$AuNPs

5.1. Production, and Characterization of Radioactive MGF-$^{198}$AuNPs

Gold presents several isotopes including radioactive isotopes—Au-198 and Au-199—for medical applications. Au-198 with 2.70-day half-life emits both $\beta$ (961 keV) and $\gamma$ radiation (411 keV $\gamma$ (96%)). Its half-life and beta energy emission allows efficient destruction of tumor cells/tumor tissue, as the $\beta$ penetration range is ideal (up to 4 mm in tissue or up to 1100 cell diameters) and 2.7 d is sufficiently long to provide crossfire effects to destroy tumor cells/tissue, while short enough to minimize radiation exposure to neighbouring non-target tissues. A distinct advantage of radioactive gold NPs is that there is no need to incorporate the isotope into every tumor cell to have a therapeutic effect because the path length of the emitted radiation is sufficient to allow effective therapy following uptake into a subpopulation of tumor cells. This makes NPs of Au-198 ideal therapeutic candidates for the effective delivery of therapeutic doses of beta emitting NPs selectively to tumor tissue and tumor cells. Au-198 allows monitoring therapeutic response because its $\gamma$ radiation allows scintigraphic imaging of various normal and tumor tissue. Scintigraphy approaches allow
evaluation of tumor retention characteristics of AuNPs, labelled with small tumor specific biomolecules or conjugated to polymeric NPs (including hydrogels)—by determining the bio-distribution of radioactive gold nanoparticles post-administration of \(^{198}\text{Au} \text{NPs}\). In order to understand the retention and pharmacokinetics of MGF functionalized gold nanoparticles (MGF-AuNPs) within prostate tumors, we have recently synthesized and fully characterized the corresponding radioactive analogue of MGF, \(^{198}\text{Au} \text{NPs}\) by labelling MGF with \(^{198}\text{AuNPs}\) (Figure 4). Mangiferin displays tumor cell avidity with high selectivity toward receptors over-expressed by a host of tumors including prostate, breast, colorectal and pancreatic tumors [38,104,105]. \(\gamma\) emission characteristics of MGF-\(^{198}\text{AuNPs}\) have been highly useful to estimate its retention within prostate and various other tumors and non-target organs. For the synthesis of radioactive MGF-\(^{198}\text{AuNPs}\), we first had to optimize the production of \(^{198}\text{Au}\) at the University of Missouri Research Reactor (MURR) facility in high radiochemical purity. The procedure optimized for the synthesis of \(^{198}\text{Au}\) is discussed in the following sections.

![Figure 4](image_url)

**Figure 4.** Synthesis and MGF corona architecture of MGF-AuNPs and MGF-\(^{198}\text{AuNPs}\).

The production protocol irradiation of natural abundance high purity gold foil to produce \(^{198}\text{Au}\) according to the following nuclear equation \(\text{Au-197}(n,\gamma) \text{Au-198}\) [38]. A neutron flux of \(8 \times 10^{13}\) n/cm\(^2\)/s at MURR was used. The irradiation times and mass of gold foil were optimized depending on the activity of \(^{198}\text{Au}\) isotope needed; typically, irradiation times were from 6 to 40 h. After each irradiation, the radioactive foil was dissolved in about 400 \(\mu\)L of aqua regia, and subsequently the mixture was heated to produce a dry residue. Following the addition of two 400-\(\mu\)L aliquots of 0.05 M HCl, the mixtures were heated to drive off the nitric acid. At this stage, the radioactive Au-198 was dissolved in optimum volumes of water to produce final solutions of \(^{198}\text{Au}\) for subsequent applications in the production of MGF-\(^{198}\text{AuNPs}\).

### 5.2. Preparation of ‘Premix’

The radioactive gold (\(^{198}\text{Au}\)) solution, as prepared above, was mixed with \(\text{Na}_2\text{AuCl}_4\) to form radioactive gold precursor (Premix) to produce total mass of radioactive \(^{198}\text{Au}\) and non-radioactive Au of 0.66 mg, and a desired specific activity, according to the required
activity in the final solutions of NPs [38]. For example, in our therapeutic investigations, the mass of $^{198}$Au was 0.082 mg (this mass was chosen because it had the required activity of 481 MBq). We therefore mixed 0.082 mg of $^{198}$Au with gold salt that had a mass of gold equal to 0.578 mg, in order to make the total mass of gold in the solution equal to 0.66 mg. All these mixtures were produced in a 2 mL solution. If lower activities were needed, then accordingly, the mass of $^{198}$Au was decreased while the mass of gold within gold salt increased, to maintain the total mass of gold at 0.66 mg [38].

5.3. Production of Radioactive MGF-$^{198}$AuNPs

It is important to note that well-optimized procedures for the synthesis of the non-radioactive MGF-AuNPs, when applied toward the synthesis of the corresponding radioactive MGF-$^{198}$AuNPs, did not work [105]. This is not surprising because the kinetics of chemical reactions at macroscopic levels often differ considerably from those at tracer levels. Therefore, we have developed a slightly modified procedure wherein the mass of MGF (1.4 mg for non-radioactive MGF-AuNPs preparation) was increased to 1.55–1.6 mg for the preparation of radioactive MGF-$^{198}$AuNPs (Figure 4). We have shown that 1.55–1.6 mg of MGF produces radioactive MGF-$^{198}$AuNPs in high radio-chemical purity with excellent reproducibility from batch to batch [38]. The production protocols involved addition of 1.55–1.6 mg of MGF to 2 mL of milli-Q water. The reaction mixtures were stirred at room temperature for 10 min, and subsequently heated under stirring at 99 °C. To this mixture of MGF, we added the radioactive gold Premix solution ($^{198}$Au + Na$_2$AuCl$_4$), which has the desired activity (14.43–481 MBq). This addition instantaneously changed the color of the reaction mixture from pale yellow to burgundy red, indicating the formation of radioactive gold nanoparticles. Such color transformations in gold nanoparticle synthesis signify the appearance of surface plasmon resonances, which are characteristic photon absorptions of surface atoms of nanosized noble metal particles, including gold. For completion of this reaction, stirring was continued for an additional 1 h at room temperature.

5.4. Characterization

Radioactive MGF-$^{198}$AuNPs were characterized by measuring the surface plasmon resonance (SPR) wavelength ($\lambda_{\text{max}}$) using UV-Vis spectroscopy, which showed a $\lambda_{\text{max}}$ peak at 545 nm [38,105]. Thin-layer chromatography (TLC) measurements were used to determine radioactive yields of MGF-$^{198}$AuNPs. Free $^{198}$Au solution moves to the solvent front in TLC, whereas $^{198}$Au-nanoparticles remain at the origin. The procedure was performed by adding 1 µL of nanoparticles solution to the origin of cellulose TLC plate. Accurate yields of radioactive gold (over 95%) were measured using a radio TLC (Bio-Scan company).

After the successful production of MGF-$^{198}$AuNPs, the next logical step was to understand its biodistribution in normal mice. Accordingly, biodistribution of MGF-$^{198}$AuNPs in normal mice was evaluated at various time points, as shown in Figure 5 [38]. It is clear from this biodistribution profile that (1) this nanomedicine agent has optimum in vivo stability with efficient clearance from blood and various non-target organs, and (2) MGF-$^{198}$AuNPs clear through the hepatobiliary system, as indicated by its liver uptake (Figure 5). These biodistribution investigations provide convincing rationale of the utility of Au-198m$\gamma$, thus allows scintigraphic imaging for the accurate assessment of the of functionalized gold nanoparticles. Considering the availability of a vast repertoire of functionalized gold nanoparticles for potential applications in nanomedicine, this investigation highlights the need to produce the corresponding Au-198 labelled analogues, to enable scintigraphic imaging investigations for gaining invaluable insights on the fate of gold nanoparticles in vivo.
Figure 5. Biodistribution profile of MGF-198AuNPs in normal mice after intravenous administration of a single dose (296 kBq/100 µL) intravenously through a tail vein. Radioactivity was measured at 30 min, 1 h, 2 h, 4 h, and 24 h post-injection, and was calculated as the percentage of injected dose (%ID) per organ [38].

We further probed into the cancer cell receptor specific features of MGF-AuNPs because the pharmacomotif of MGF comprised of a glucose moiety and polyphenol (Figure 4) has strong avidity and specificity toward Laminin receptor proteins, which are signatures of various tumor cells.

5.5. Laminin 67 Receptor-Mediated Cellular Internalization of MGF-AuNPs

To study the internalisation of MGF-AuNPs into tumor cells, prostate tumor (PC-3) cells derived from human prostate tumors were incubated with MGF-AuNPs and subsequently characterized. Both transmission electron microscopy and dark field microscopy indicated that these NPs are effectively internalized into tumor cells. Further, extensive neutron activation analysis (NAA) results, to quantify gold content in PC-3 cells, as well as receptor blocking experiments, have established that the endocytosis of MGF-AuNPs within PC-3 cells are mediated through Lam 67 receptors [38,105]. These experiments show the selectivity of MGF-AuNPs for prostate cancer cells, a critical aspect to target primary disease without secondary morbidity. As shown in Figure 6, MGF-AuNPs are endocytosed into PC-3 cells showing localization in vacuoles, as well as in the cytoplasm without disturbing the nucleus. MGF-AuNP, which are homed into tumor cells, appear to remain intact, suggesting high avidity of MGF-AuNP toward laminin receptors over expressed by tumor cells [105]. The dark field microscopic images, as shown in Figure 6, corroborate TEM images—thus confirming endocytosis of MGF-AuNPs in tumor cells [105]. These results demonstrating the selectivity of MGF-AuNPs for prostate cancer cells, prompted a detailed pre-clinical in vivo tumor retention and therapeutic efficacy investigation of MGF-198AuNPs.
Figure 6. Dark field microscopic images (40×) investigating Lam 67 receptor avidity of mangiferin gold nanoparticles (MGF-AuNPs) towards prostate cancer cells. (A) PC-3 cells treated with MGF-AuNPs (8.2 µg/mL) and 2 hr incubation; (B) identical PC-3 cells treatment with MGF-AuNPs, following pre-treatment with laminin receptor antibody. Nuclei appear blue, cytoplasm red and NPs green in the images. (C) TEM images corroborate endocytosis of MGF-AuNPs in PC3-cells.

5.6. Pre-Clinical In Vivo Tumor Retention and Therapeutic Efficacy Investigations of MGF-AuNPs

Biodistribution of radioactive gold nanoparticles, post-administration of $^{198}$AuNPs, as synthesized above, was undertaken to evaluate the retention of these NPs in prostate tumors. We have performed in vivo studies of intratumoral administration of MGF-$^{198}$AuNPs (148 kBq/30µL for each tumor) using SCID mice (n = 5) bearing human prostate cancer xenografts. The biodistribution and tumor retention characteristics are shown in Figure 7.

The biodistribution results have confirmed that the percentage of injected dose within tumors (%ID), especially within prostate tumors at various time points, was 80.98 ± 13.39% at 30 min, increasing to 86.68 ± 3.58% at 2 h, and remained at 79.82 ± 10.55% at 24 h. Overall, there was minimal/no leakage of MGF-$^{198}$AuNPs in the liver. The (%ID) in liver was 10.65 ± 8.31% at 24 h, indicating that a small number of NPs were cleared by the reticuloendothelial system (RES) to the liver. In addition, there was very low leakage of injected dose into stomach and feces, 0.10 ± 0.16% of injected dose in stomach at 30 min decreasing to 0.02 ± 0.02% at 24 h, and 0.0% of injected dose in feces at 30 min increasing to 2.20 ± 4.51% at 24 h. These results show that the main route of clearance is via the digestive system through the feces. In contrast, there was no noticeable leakage into blood and lung and other organs. Therefore, these results from intratumoral investigations have demonstrated that MGF-$^{198}$AuNPs have excellent ability to be retained within the tumor with very minimum leakage to non-target organs. The high tumor retention with concomitant limited leakage of MGF-$^{198}$AuNPs are two key factors to minimize/eliminate systemic toxicity, and thus provide compelling scientific rationale for the future utility of this nanoradiopharmaceutical in tumor therapy.
Critical step in converting active disease to static disease and thus stopping metastases. These findings support the effectiveness of intratumoral delivery of the MGF-198 AuNPs in managing the primary tumor location, a critical step in converting active disease to static disease and thus stopping metastases.

Figure 7. Tumor selectivity and retention of MGF-198 AuNPs in tumors at 30 min, 1 h, 2 h, 4 h, and 24 h after direct injection of single dose of MGF-198 AuNPs (4.0 µCi/30 µL) in prostate tumor. In this figure, radioactivity obtained from different organs was calculated as the percentage of injected dose (%ID) of each organ using SCID mice implanted with prostate tumor xenografts.

5.7. Therapeutic Efficacy of MGF-198 AuNPs Nanoradiotherapeutic Agent

Mice with severe combined immunodeficiency (SCIDs) bearing a flank model of human prostate cancer, derived from a subcutaneous implant of 10 million PC-3 cells, were used for therapeutic efficacy and pharmacokinetic studies of MGF-198 AuNPs. Therapeutic efficacy data from the single-dose radiotherapy through intratumoral administration of MGF-198 AuNPs (5 MBq) in PC-3 bearing SCID mice are shown in Figure 8. The end-of-study biodistribution on day 42 showed that 64.7. ± 6.5 %ID (mean ± sem; n = 5) remained in the residual tumor, while 13.8. ± 4.2 %ID was noted for carcass and 1.5. ± 0.8 %ID for the liver. Retention in other tissues was negligible, with radioactivity near background levels for blood, heart, lung, spleen, intestines, stomach, bone, brain and skeletal muscle. There was a significant reduction in tumor volume (87%), four weeks after a single intratumoral dose of MGF-198 AuNPs with minimal uptake in non-target organs (Figure 8). The therapeutic efficacy demonstrated for MGF-198 AuNPs confirm its ability to inhibit tumor growth, because tumors harvested from the treatment groups consisted largely of necrotic tissue, indicating extensive tumor cell death. The tolerability of MGF-198 AuNPs in vivo has been established by monitoring the body weight and blood parameters in a SCID mice study, in both treated and control groups of animals. The treatment group showed only transient weight loss with recovery to normal weight without any early terminations. White and red blood cell, platelet, and lymphocytes levels within the treatment group resembled those of the normal mice without tumors. The overall health status and blood measures of the MGF-198 AuNP-treated animals indicate that the radiotherapy was not only effective, but also well tolerated. These findings support the effectiveness of intratumoral delivery of the nanoradiotherapeutic agent MGF-198 AuNPs in managing the primary tumor location, a critical step in converting active disease to static disease and thus stopping metastases.
of care treatment \[104\]. The bar chart in Figure 9 shows that treatment of patients with MGF-
clinical benefits compared to patients in the study (Arm A) who received only the standard
drug cocktail along with the "standard of care treatment" (Arm B) exhibited measurable
agency) for conducting clinical trials in human patients. Patients treated with a MGF-AuNP
tumors in a dose dependent fashion \[104\]. These encouraging pre-clinical results prompted
trial of this nanomedicine agent in human patients. After fully
rays. It was therefore important to investigate the therapeutic effects of the non-radioactive
X
a highly potent cocktail of therapeutic doses from photoelectric, Auger electrons and
interaction of radioactive Au-198 atoms with the non-radioactive Au atoms could generate
MGF-
treatment group (\(p = 0.04\)). The therapeutic effect was maintained
over a three-week period.

In order to estimate the tumor and local tissue doses in MGF-\(^{198}\)AuNPs for prostate
cancer radiotherapy in human patients, we have recently performed Monte-Carlo N-
Particle code calculations. The overall objective of this investigation was to estimate the
dose distribution delivered by radioactive gold nanoparticles (\(^{198}\)AuNPs or \(^{199}\)AuNPs) to
the tumor inside the human prostate, as well as to the normal tissues surrounding the
tumor using Monte-Carlo N-Particle code (MCNP-6.1.1 code) \[57\]. According to the MCNP
re-sults, \(^{198}\)AuNPs present realistic potential for use in treating prostate and other solid
cancers and for imaging purposes. In summary, the preclinical therapeutic efficacy studies,
and the detailed toxicity studies of MGF-\(^{198}\)AuNPs, provide compelling evidence for the
clinical translation of this nanotherapeutic agent for use in treating prostate and related
solid tumors in human patients. Therefore, future studies will focus on pilot clinical trials
of MGF-\(^{198}\)AuNPs, in prostate tumor bearing patients, in order to seek approval from
regulatory agencies (FDA) for the utility of this new nanomedicine agent in oncology.

5.8. Clinical Trials of MGF-AuNPs in Human Cancer Patients

As discussed above, the production of MGF-\(^{198}\)AuNPs is inherently associated with
the presence of non-radioactive analogue MGF-AuNPs (Figure 9). In fact, samples of
MGF-\(^{198}\)AuNPs contain about 95% of the non-radioactive gold atoms as MGF-AuNPs. The
interaction of radioactive Au-198 atoms with the non-radioactive Au atoms could generate
a highly potent cocktail of therapeutic doses from photoelectric, Auger electrons and X
rays. It was therefore important to investigate the therapeutic effects of the non-radioactive
MGF-AuNPs through a pilot clinical trials investigation in human patients. After fully
establishing doses at which MGF-AuNPs caused no toxicity concerns in vivo, a pilot clinical
trial of this nanomedicine agent in human patients with triple negative breast cancers was
initiated. This pilot human clinical trial was approved by AYUSH—a government of India
regulatory agency.

Detailed in vitro and in vivo investigations in breast tumor bearing mice established
unequivocally that MGF-AuNPs are highly effective in controlling the growth of breast
tumors in a dose dependent fashion \[104\]. These encouraging pre-clinical results prompted
seeking permission from regulatory authorities (AYUSH—a government of India regulatory
agency) for conducting clinical trials in human patients. Patients treated with a MGF-AuNP
drug cocktail along with the “standard of care treatment” (Arm B) exhibited measurable
clinical benefits compared to patients in the study (Arm A) who received only the standard
of care treatment \[104\]. The bar chart in Figure 9 shows that treatment of patients with MGF-
AuNPs produced measurable therapeutic efficacy in reducing the tumor burden by 15–20%, as compared to the patient set which received only the standard of care chemotherapy treatment. These results indicate the tremendous clinical benefits of using mixtures of MGF-AuNPs and MGF-^{198}\text{AuNPs} in clinically translating phytochemicals functionalized gold nanoparticles for treating various types of human cancers (Figure 9). Therefore, our extensive pre-clinical and clinical results, taken together, provide complete evidence that the mangiferin functionalized radioactive gold nanoparticles present realistic promise as a new nanoradiotherapeutic agent for treating prostate, breast and various types of solid tumors in human patients.

5.8. Clinical Trials of MGF-AuNPs in Human Cancer Patients
As ... (a) radionuclides for NPs radiolabeling; (b) design and development of NPs; (c) chemical-based synthesis of NPs—general aspects of production; (d) radiation-based synthesis of NPs; and (e) production, characterization, and pre-clinical/clinical investigations of radioactive MGF-^{198}\text{AuNPs}. The radiolabeling protocols, tumor specific peptides and tumor avid small molecules developed for radiolabeling polymeric NPs, hydrogels and metallic NPs—have, individually and collectively, generated new science and a nanotechnology knowledge base for use in the design and development of next generation nanoradiopharmaceuticals.

6. Conclusions
The CRP entitled ‘Nanosized delivery systems for radiopharmaceuticals’ which was initiated in 2014 has resulted in major discoveries, and breakthroughs—all leading to the development of new chemical and radiation-based techniques for the development of a number of metallic and non-metallic nanoparticles. Here, we have attempted to summarize progress achieved in this CRP on the following fronts: (a) radionuclides for NPs radiolabeling; (b) design and development of NPs; (c) chemical-based synthesis of NPs—general aspects of production; (d) radiation-based synthesis of NPs; and (e) production, characterization, and pre-clinical/clinical investigations of radioactive MGF-^{198}\text{AuNPs}. The radiolabeling protocols, tumor specific peptides and tumor avid small molecules developed for radiolabeling polymeric NPs, hydrogels and metallic NPs—have, individually and collectively, generated new science and a nanotechnology knowledge base for use in the design and development of next generation nanoradiopharmaceuticals.

Author Contributions: Conceptualization, A.R.J., A.S., B.O.-G., A.D., J.A.O.J. and K.V.K.; methodology, W.P., B.O.-G., T.M.S., L.M.-A., M.G., A.B.L., H.Y., C.D., M.M., S.M.J., I.U.K., P.U., S.C.J.L. and K.V.K.; validation, B.O.-G., W.P., T.M.S., L.M.-A. and C.D.; formal analysis, K.V.K., B.O.-G., A.R.J. and T.M.S.; investigation, K.V.K., T.M.S., B.O.-G., M.G., M.M. and I.U.K.; resources, B.O.-G., K.V.K., L.M.-A., W.P. and T.M.S.; data curation, B.O.-G., W.P., T.M.S., M.M. and L.M.-A.; writing—original draft preparation, B.O.-G., T.M.S., W.P. and K.V.K.; writing—review and editing, K.V.K. and B.O.-G.; visualization, T.M.S., B.O.-G. and K.V.K.; supervision, A.R.J.; project administration, A.R.J., A.S. and J.A.O.J.; funding acquisition, A.R.J., A.S. and J.A.O.J. All authors have read and agreed to the published version of the manuscript.

Funding: The funding for performing this international IAEA/CRP with the code F22064 was approved and provided by Research Contracts Administration Section at IAEA under the program for radionuclides production for non-communicable diseases. The Italian team of the University of Palermo acknowledges the FFR_D09-Fondo di Finanziamento per la Ricerca di Ateneo 2018/2021. Polish teams were also supported by The Polish Ministry of Science and Higher Education research funds. Pre-clinical and clinical investigations of MGF-AuNPs were supported from funds...
through Dhanvantari Nano Ayushadi company (DNA), with logistical support from the Institute of Green Nanotechnology, University of Missouri Research Reactor, University of Missouri, Columbia, Missouri, USA. Financial support was received from the Malaysian Nuclear Agency for research activities under this CRP. IPEN-CNEN contribution was funded by IAEA CRP F22064, CNPq contracts 442527/2019-5, 315530/2018-9 and 406923/2021-3, FAPESP, and contract 2017/50332-0. Experiments carried out at Instituto Nacional de Investigaciones Nucleares were supported by the Mexican Ministry of Science under grant CONACYT-CB-A1S38087.

**Institutional Review Board Statement:** Not applicable.

**Informed Consent Statement:** Not applicable.

**Data Availability Statement:** Extensive literature references have been cited in the review article.

**Acknowledgments:** The authors wish to thank all IAEA CRP (F22064) chief scientific investigators, especially the Agreement Holders from developed member states who shared their knowledge and expertise with the whole team. We deeply appreciate highly valuable scientific edits provided by Melissa DENECKE, Director (Division of Physical and Chemical Sciences), NAPC, IAEA, Vienna, Austria. The edits of DENECKE have improved the scientific quality of this review article. This CRP became a stellar success with exemplary collaborative spirit from all the participating subject experts from member countries and through support from the Nuclear Application Coordinated Activity section at IAEA. SCJ Loo would like to acknowledge the financial support from the School of Materials Science and Engineering, Nanyang Technological University, Singapore.

**Conflicts of Interest:** The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

**Abbreviations**

| Symbol                  | Description                                                                 |
|-------------------------|-----------------------------------------------------------------------------|
| 131I-doped Ag-PEG NPs   | Polyethylene glycol capped silver NPs doped with I-131 radionuclide         |
| AFCuONPs                | Aspergillus flavus synthesized copper oxide NPs                              |
| AuNPs                   | Gold nanoparticles                                                           |
| AuNPs-BSA               | Gold nanoparticles capped with bovine serum albumin                         |
| AuNP-Tyr³-Octreotide    | Gold nanoparticles functionalized with Tyr(3)-octreotide peptide             |
| AX-encapsulated ¹⁹⁸AuNPs| Arabinosyxylan-encapsulated functionalized radioactive gold nanoparticles    |
| BN-PLGA(PTX)            | Poly lactic-co-glycolic acid nanoparticles loaded with paclitaxel (PTX) and functionalized with bombesin |
| CSNPs-PEI-folate        | Chitosan nanoparticles functionalized with folate and polyethyleneimine     |
| DN(AuNP)-folate-BN      | Dendrimer(PAMAM-G4)-folate-bombesin with gold nanoparticles (AuNPs) in the dendritic cavity |
| DN(C19)-CXCR4           | Dendrimer encapsulating C19 and functionalized to target CXCR4              |
| DOTA-BN-TMC-MNPs        | Trimethyl chitosan superparamagnetic nanoparticles functionalized with DOTA-bombesin |
| DOTA-DN(PTX)-BN         | Polyamidoamine dendrimer (DN) loaded with paclitaxel (PTX) and functionalized with DOTA-bombesin |
| DOTA-HA-PLGA(MTX)       | Poly lactic-co-glycolic acid nanoparticles loaded with methotrexate (MTX) and functionalized with hyaluronic acid (HA) and DOTA |
| DOX-AuNPs               | Gold nanoparticles loaded with doxorubicin                                  |
| MGF-AuNPs               | Mangiferin functionalized radioactive gold nanoparticles                     |
| MIONPs                  | Magnetic iron oxide nanoparticles platform                                    |
| PAMAM-Tyr³-Octreotide   | Polyamidoamine (PAMAM) dendrimers functionalized with Tyr(3)-Octreotide peptide |
| SeNPs                   | Selenium nanoparticles                                                       |
| VitC-SeNPs              | Selenium nanoparticles coated with vitamin C                                 |
NP Nanoparticle
RGD arginine-glycine-aspartic acid
PMMA Poly(methyl methacrylate)
PLGA Poly(lactide-co-glycolide acid)
DOTA 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid
CXCR4 C-X-C Motif Chemokine Receptor 4
TEM Transmission electron microscopy
AFM Atomic force microscopy
BBN Bombesin
PAA poly(acrylic acid)
PAA-PEO IPC Poly(acrylic acid)-poly(ethylene oxide) (PAA-PEO) interpolymer complexes
PVP Polyvinylpyrrolidone
PVP-g-AA-Folate Polyvinyl pyrrolidone with acrylic acid grafts decorated with folic acid
PVP-g-AA_Doxo Polyvinyl pyrrolidone with acrylic acid grafts decorated with Doxorubicin
PVP-g-AA-SiRNA Polyvinyl pyrrolidone with acrylic acid grafts decorated with SilencingRNA
PVP-g-AA-AntiMIR Polyvinyl pyrrolidone-based nanogels with acrylic acid grafts conjugated to the amino-terminated AntimiR-31
PVP-g-AA-Insulin Polyvinyl pyrrolidone- nanogels with acrylic acid grafts, conjugated to insulin
PVP-g-APMAM Polyvinyl pyrrolidone-based nanogels with (3-N-aminopropyl) methacrylamide
CS-DC NPs Deoxycholate conjugated chitosan Nanoparticles
pPEGMA-CS-DC NPs Poly(ethylene glycol) monomethacrylate grafted chitosan deoxycholate amphiphilic Nanoparticles
pSMA-CS NPs Poly(stearyl methacylate) grafted chitosan Nanoparticles
pSMA-CS-PPD NPs Piperidine conjugate poly(stearyl)-grafted chitosan Nanoparticles
WSCS nanocolloids Water-soluble chitosan nanocolloids
SF nanocolloids Silk fibrin nanocolloids
WSCS-DOTA-BBN NPs Water-soluble chitosan conjugated DOTA Nanoparticles and Bombesin peptide
AuNPs-CS Gold Nanoparticles capped with Chitosan
AuNPs-WSCS Gold nanoparticles capped with water-soluble chitosan
AuNPs-WSCS-DOTA-BBN Gold nanoparticles capped with water-soluble chitosan conjugated DOTA chelator and BBN peptide
AuNPs-WSCS-GA-DOTA-BBN Gold nanoparticles, stabilized with Gum Arabic, and capped with water-soluble chitosan conjugated DOTA chelator and BBN peptide
bioHNPs AuNPs coated with human albumin multilayers
SCID Severe combined immunodeficient mice

References
1. Kumar, P.P.; Lim, D.-K. Gold-Polymer Nanocomposites for Future Therapeutic and Tissue Engineering Applications. *Pharmaceutics* 2022, 14, 70. [CrossRef] [PubMed]
2. Palombarini, F.; Masciarelli, S.; Incocciati, A.; Liccardo, F.; Di Fabio, E.; Iazzetti, A.; Fabrizi, G.; Fazi, F.; Macone, A.; Bonamore, A. Self-assembling ferritin-dendrimer nanoparticles for targeted delivery of nucleic acids to myeloid leukemia cells. *J. Nanobiotechnol.* 2021, 19, 172. [CrossRef] [PubMed]
3. Mbatha, L.S.; Maiyo, F.; Daniels, A.; Singh, M. Dendrimer-coated gold nanoparticles for efficient folate-targeted mRNA delivery in vitro. *Pharmaceutics* 2021, 13, 900. [CrossRef] [PubMed]
4. Joseph, C.; Daniels, A.; Singh, S.; Singh, M. Histidine-Tagged Folate-Targeted Gold Nanoparticles for Enhanced Transgene Expression in Breast Cancer Cells In Vitro. *Pharmaceutics* 2022, 14, 53. [CrossRef]
5. Fan, L.; Wang, W.; Wang, Z.; Zhao, M. Gold nanoparticles enhance antibody effect through direct cancer cell cytoxicity by differential regulation of phagocytosis. *Nat. Commun.* 2021, 12, 6371. [CrossRef]
6. Ayub, A.; Wettig, S. An Overview of Nanotechnologies for Drug Delivery to the Brain. *Pharmaceutics* 2022, 14, 224. [CrossRef]
7. Yang, Z.; Wang, D.; Zhang, C.; Liu, H.; Hao, M.; Kan, S.; Liu, D.; Liu, W. The Applications of Gold Nanoparticles in the Diagnosis and Treatment of Gastrointestinal Cancer. *Front. Oncol.* 2022, 11, 819329. [CrossRef]

8. Yafouf, M.; Ousaid, A.; Khayati, Y.; El Otmani, I.S. Gold nanoparticles as a drug delivery system for standard chemotherapeutics: A new lead for targeted pharmacological cancer treatments. *Sci. Afr.* 2021, 11, e00685. [CrossRef]

9. Kadkhoda, J.; Aghanejad, A.; Safari, B.; Barar, J.; Rasta, S.H.; Davaran, S. Aptamer-conjugated gold nanoparticles for targeted pacitaxel delivery and photothermal therapy in breast cancer. *J. Drug Deliv. Sci. Technol.* 2022, 67, 102954. [CrossRef]

10. Farooq, M.U.; Novosad, V.; Rozhkova, E.A.; Wali, H.; Ali, A.; Fateh, A.A.; Neogi, P.B.; Neogi, A.; Wang, Z. Gold nanoparticles-enabled efficient dual delivery of anticancer therapeutics to Hela cells. *Sci. Rep.* 2018, 8, 2907. [CrossRef]

11. Ferro-Flores, G. Targeted Nanomedicines: In the Right Route Towards Improved Therapies. *Curr. Cancer Ther. Rev.* 2020, 16, 3–4. [CrossRef]

12. Trujillo-Nolasco, M.; Morales-Avila, E.; Cruz-Nova, P.; Katti, K.V.; Ocampo-Garcia, B. Nanoradiopharmaceuticals Based on Alpha Emitters: Recent Developments for Medical Applications. *Pharmaceutics* 2021, 13, 1123. [CrossRef] [PubMed]

13. Klain, M.; Zampella, E.; Nappi, C.; Nicolai, E.; Ambrosio, R.; Califaretti, E.; Lamartina, L.; Schlumberger, M.; Deandreis, D.; Salvatore, D. Advances in Functional Imaging of Differentiated Thyroid Cancer. *Cancers* 2021, 13, 4748. [CrossRef] [PubMed]

14. Jeon, J. Review of Therapeutic Applications of Radiolabeled Functional Nanomaterials. *Int. J. Mol. Sci.* 2019, 20, 2323. [CrossRef] [PubMed]

15. Aghevlian, S.; Cai, Z.L.; Lu, Y.J.; Hedley, D.W.; Winnik, M.A.; Reilly, R.M. Radioimmunotherapy of PANC-1 Human Pancreatic Cancer Xenografts in NRG Mice with Panitumumab Metal-Chelating Polymers Complexed to Lu-177. *Mol. Pharm.* 2019, 16, 768–778. [CrossRef]

16. Ocampo-Garcia, B.E.; Ferro-Flores, G.; De Leon-Rodriguez, L.M.; Santos-Cuevas, C.L.; Morales-Avila, E.; de Murphy, C.A.; Pedraza-Lopez, M.; Medina, L.A.; Camacho-Lopez, M.A. Tc-99m-labelled gold nanoparticles capped with HYNIC-peptide/mannose for sentinel lymph node detection. *Nucl. Med. Biol.* 2011, 38, 1–11. [CrossRef]

17. Oroco-Rodriguez, E.; Ferro-Flores, G.; Santos-Cuevas, C.L.; Ramirez, F.D.M.; Ocampo-Garcia, B.E.; Azorin-Vega, E.; Sanchez-Garcia, F.M. Two Novel Nanosized Radiolabeled Analogues of Somatostatin for Neuroendocrine Tumor Imaging. *J. Nanosci. Nanotechnol.* 2015, 15, 4159–4169. [CrossRef]

18. Mendoza-Sánchez, A.N.; Ferro-Flores, G.; Ocampo-Garcia, B.E.; Morales-Avila, E.; Ramirez, F.D.M.; De León-Rodriguez, L.M.; Santos-Cuevas, C.L.; Medina, L.A.; Rojas-Calderon, E.L.; Camacho-Lopez, M.A. Lys-3-Bombesin Conjugated to99mTc-Labelled Gold Nanoparticles for In Vivo Gastrin Releasing Peptide-Receptor Imaging. *J. Biomed. Nanotechnol.* 2010, 6, 375–384. [CrossRef]

19. Ocampo-Garcia, B.; Ferro-Flores, G.; Morales-Avila, E.; de Maria Ramirez, F. Kit for preparation of multimeric receptor-specific 99mTc-radiopharmaceuticals based on gold nanoparticles. *Nucl. Med. Commun.* 2011, 32, 1095–1104. [CrossRef]

20. Morales-Avila, E.; Ferro-Flores, G.; Ocampo-Garcia, B.E.; De Leon-Rodriguez, L.M.; Santos-Cuevas, C.L.; Garcia-Beccera, R.; Medina, L.A.; Gomez-Olivar, L. Multimetric system of 99mTc-labeled gold nanoparticles conjugated to c (RGDfK (C)) for molecular imaging of tumor α (v) β (3) expression. *Bioconjug Chem.* 2011, 22, 913–922. [CrossRef]

21. Isaac-Olive, K.; Ocampo-Garcia, B.E.; Aranda-Lara, L.; Santos-Cuevas, C.L.; Jimenez-Mancilla, N.P.; Luna-Gutierrez, M.A.; Medina, L.A.; Nagarajan, B.; Sabnis, N.; Raut, S.; et al. Tc-99m-HYNIC-N-dodecylamide: A new hydro-phybic tracer for labelling reconstituted high-density lipoproteins (rHDL) for radioimaging. *Nanoscale* 2019, 11, 541–551. [CrossRef] [PubMed]

22. El-Ghareb, W.I.; Swidan, M.M.; Ibrahim, I.T.; Abd El-Bary, A.; Tadros, M.I.; Sakr, T.M. Tc-99m-doxorubicin-loaded gallic acid-gold nanoparticles (Tc-99m-DOX-loaded GA-Au NPs) as a multifunctional theranostic agent. *Int. J. Pharm.* 2020, 586, 119514. [CrossRef] [PubMed]

23. Sakr, T.M.; Morsy, S.A.; Mahmoud, N.A.; Rashed, H.M.; Abd El-Rehim, H.; Khoobchandani, M.; Katti, K.K.; Katti, K.V. Preparation, characterization, cytotoxicity and biological evaluation of 99mTc-Doxorubicin-Micelle conjugate functionalized gold nanoparticles as a new generation of theranostic radiopharmaceutical. *Preprints* 2018, 2018080331.

24. Jimenez-Mancilla, N.; Ferro-Flores, G.; Santos-Cuevas, C.; Ocampo-Garcia, B.; Luna-Gutierrez, M.; Azorin-Vega, E.; Isaac-Olive, K.; Camacho-Lopez, M.; Torres-Garcia, E. Multifunctional targeted therapy system based on Tc-99m/Lu-177-labeled gold nanoparticles-Tat(49-57)-Lys-(3) bombesin internalized in nuclei of prostate cancer cells. *J. Label. Compd. Radiopharm.* 2013, 56, 663–671. [CrossRef] [PubMed]

25. Santos-Cuevas, C.L.; Ferro-Flores, G.; de Murphy, C.A.; Ramirez, F.D.; Luna-Gutierrez, M.A.; Pedraza-Lopez, M.; Garcia-Beccera, R.; Ordaz-Rosado, D. Design, preparation, in vitro and in vivo evaluation of Tc-99m-N2S2-Tat(49-57)-bombesin: A target-specific hybrid radiopharmaceutical. *Int. J. Pharm.* 2009, 375, 75–83. [CrossRef]

26. Dash, A.; Pillai, M.R.A.; Knapp, F.F. Production of Lu-177 for Targeted Radiounclide Therapy: Available Options. *Nucl. Med. Mol. Imaging* 2015, 49, 85–107. [CrossRef]

27. Luna-Gutierrez, M.; Ferro-Flores, G.; Ocampo-Garcia, B.E.; Santos-Cuevas, C.L.; Jimenez-Mancilla, N.; De Leon-Rodriguez, L.M.; Azorin-Vega, E.; Isaac-Olive, K. A Therapeutic System of Lu-177-labeled Gold Nanoparticles-RGD Internalized in Breast Cancer Cells. *J. Mex. Chem.* 2013, 57, 212–219.

28. Vichlis-Juarez, A.; Ferro-Flores, G.; Santos-Cuevas, C.; Morales-Avila, E.; Ocampo-Garcia, B.; Diaz-Nieto, L.; Luna-Gutierrez, M.; Jimenez-Mancilla, N.; Pedraza-Lopez, M.; Gomez-Olivar, L. Molecular Targeting Radiotherapy with Cyclo-RGDfK(C) Peptides Conjugated to Lu-177-Labeled Gold Nanoparticles in Breast Cancer Mice. *J. Biomed. Nanotech.* 2014, 10, 393–404. [CrossRef]
29. Gibbens-Bandala, B.; Morales-Avila, E.; Ferro-Flores, G.; Santos-Cuevas, A.; Luna-Gutierrez, M.; Ramirez-Nava, G.; Ocampo-Garcia, B. Synthesis and Evaluation of Lu-177-DOTA-DN(PTX)-BN for Selective and Concomitant Radio and Drug-Therapeutic Effect on Breast Cancer Cells. Polymers 2019, 11, 1572. [CrossRef]

30. Gibbens-Bandala, B.; Morales-Avila, E.; Ferro-Flores, G.; Santos-Cuevas, A.; Melendez-Alafort, L.; Trujillo-Nolasco, M.; Ocampo-Garcia, B. Lu-177-Bombesin-PLGA (paclitaxel): A targeted controlled-release nanomedicine for bimodal therapy of breast cancer. Mater Sci. Eng. C Mater. Biol. Appl. 2019, 105, 110043. [CrossRef]

31. Trujillo-Nolasco, M.; Cruz-Nova, P.; Ferro-Flores, G.; Gibbens-Bandala, B.; Morales-Avila, E.; Aranda-Lara, L.; Vargas, M.; Ocampo-Garcia, B. Development of Lu-177-DN(C19)-CXCR4 Ligand Nanosystem for Combinatorial Therapy in Pancreatic Cancer. J. Biomed. Nanotech. 2021, 17, 263–279. [CrossRef] [PubMed]

32. Gonzalez-Ruiz, A.; Ferro-Flores, G.; Jimenez-Mancilla, N.; Escudero-Castellanos, A.; Ocampo-Garcia, B.; Luna-Gutierrez, M.; Santos-Cuevas, C.; Morales-Avila, E.; Isaac-Olive, K. In vitro and in vivo synergistic effect of radiotherapy and plasmonic photothermal therapy on the viability of cancer cells using Lu-177-Au-NLS-RGD-Aptamer nanoparticles under laser irradiation. J. Radioanal. Nucl. Chem. 2018, 318, 1913–1921. [CrossRef]

33. Mendoza-Nava, H.; Ferro-Flores, G.; Ramirez, F.D.; Ocampo-Garcia, B.; Santos-Cuevas, C.; Azorin-Vega, E.; Jimenez-Mancilla, N.; Luna-Gutierrez, M.; Isaac-Olive, K. Fluorescent, Plasmonic, and Radiotherapeutic Properties of the Lu-177-Dendrimer-AuNP-Folate-Bombesin Nanoprobe Located Inside Cancer Cells. Mol. Imaging. 2017, 16, 1536012117704768. [CrossRef] [PubMed]

34. Ancira-Cortez, A.; Ferro-Flores, G.; Jimenez-Mancilla, N.; Morales-Avila, E.; Al-Yasiri, A.; Ocampo-Garcia, B.; Santos-Cuevas, C.; Escudero-Castellanos, A.; Luna-Gutierrez, M. Synthesis, chemical and biochemical characterization of LuO2-iPSMA nanoparticles activated by neutron irradiation. Mater. Sci. Eng. C Mater. Biol. Appl. 2020, 117, 111335. [CrossRef] [PubMed]

35. Goel, S.; Chen, F.; Ehlerding, E.B.; Cai, W.B. Intrinsically Radiolabeled Nanoparticles: An Emerging Paradigm. Small 2014, 10, 3825–3830. [CrossRef] [PubMed]

36. Trujillo-Benitez, D.; Ferro-Flores, G.; Morales-Avila, E.; Ancira-Cortez, A.; Ocampo-Garcia, B.; Santos-Cuevas, C.; Escudero-Castellanos, A.; Luna-Gutierrez, M.; Azorin-Vega, E. Synthesis and Biochemical Evaluation of Samarium-153 Oxide Nanoparticles Functionaized with iPSMA-Bombesin Heterodimeric Peptide. J. Biomed. Nanotech. 2020, 16, 689–701. [CrossRef]

37. Ancira-Cortez, A.; Trujillo-Benitez, D.; Jimenez-Mancilla, N.; Santos-Cuevas, C.; Morales-Avila, E.; Ferro-Flores, G. Synthesis and physicochemical characterization of Lu and Sm sesquioxide nanoparticles by precipitation-calcination and pulsed laser ablation in liquids. Mater. Chem. Phys. 2022, 255, 125229. [CrossRef]

38. Al-Yasiri, A.Y.; Khoobchandani, M.; Cutler, C.S.; Watkinson, L.; Carmack, T.; Smith, C.J.; Kuchuk, M.; Loyalka, S.K.; Lugao, A.B.; Katti, K.V. Mangiferin functionalized radioactive gold nanoparticles (MGF-(198)AuNPs) in prostate tumor therapy: Green nanotechnology for production, in vivo tumor retention and evaluation of therapeutic efficacy. Dalton Trans. 2017, 46, 14561–14571. [CrossRef]

39. Chanda, N.; Kan, P.; Watkinson, L.D.; Shukla, R.; Zambre, A.; Carmack, T.L.; Engelbrecht, H.; Lever, J.R.; Katti, K.; Fent, G.M.; et al. Radioactive gold nanoparticles in cancer therapy: Therapeutic efficacy studies of GA-(AuNP)-Au-198 nanoconstruct in prostate tumor-bearing mice. Nanomed. Nanotechnol. Biol. Med. 2010, 6, 201–209. [CrossRef]

40. Cutler, C.; Al-Yasiri, A.; Kuchuk, M.; Loyalka, S.; Watkinson, L.; Carmack, T.; Smith, C.J.; Katti, K. Comparison of in vivo uptake of radioactive gold nanoparticles formulated using phytochemicals. J. Nucl. Med. 2015, 56, 1267.

41. Katti, K.V. Renaissance of nuclear medicine through green nanotechnology: Functionalized radioactive gold nanoparticles in cancer therapy—my journey from chemistry to saving human lives. J. Radioanal. Nucl. Chem. 2016, 309, 5–14. [CrossRef]

42. Katti, K.V.; Khoobchandani, M.; Thipe, V.C.; Al-Yasiri, A.Y.; Katti, K.K.; Loyalka, S.K.; Sakr, T.M.; Lugao, A.B. Prostate tumor therapy advances in nuclear medicine: Green nanotechnology toward the design of tumor specific radioactive gold nanoparticles. J. Radioanal. Nucl. Chem. 2018, 318, 1737–1747. [CrossRef]

43. Hajiramezanali, M.; Atyabi, F.; Mosayebnia, M.; Akhlaghi, M.; Geramifar, P.; Jalilian, A.R.; Mazidi, S.M.; Yousefnia, H.; Shahhosseini, S.; Beiki, D. Ga-68-radiolabeled bombesin-conjugated to trimethyl chitosan-coated superparamagnetic nanoparticles for molecular imaging: Preparation, characterization and biological evaluation. Int. J. Nanomed. 2019, 14, 2591–2605. [CrossRef] [PubMed]

44. Essa, B.M.; El-Mohty, A.A.; El-Hashash, M.A.; Sakr, T.M. Tc-99m-citrate-gold nanoparticles as a tumor tracer: Synthesis, characterization, radiolabeling and in-vivo studies. Radiochim. Acta 2020, 108, 809–819. [CrossRef] [PubMed]

45. Sakr, T.M.; El-Hashash, M.A.; El-Mohty, A.A.; Essa, B.M. Tc-99m-gallic-gold nanoparticles as a new imaging platform for tumor targeting. Appl. Radiat. Isot. 2020, 164, 109269. [CrossRef]

46. Ocampo-Garcia, B.; Gibbens-Bandala, B.; Morales-Avila, E.; Melendez-Alafort, L.; Khoobchandani, M.; Trujillo-Nolasco, M.; Katti, K.K. Dual-Targeted Therapy and Molecular Imaging with Radiolabeled Nanoparticles. In Dual-Targeted Therapy and Molecular Imaging with Radiolabeled Nanoparticles. In Applied Radiotracer Chemistry IX; Springer: Cham, Switzerland, 2019.

47. El-Safoury, D.M.; Ibrahim, A.B.; El-Setouhy, D.A.; Khovessah, O.M.; Motalab, M.A.; Sakr, T.M. Gold nanoparticles for Tc-99m-doxorubicin delivery: Formulation, in vitro characterization, comparative studies in vivo stability and biodistribution. J. Radioanal. Nucl. Chem. 2021, 328, 325–338. [CrossRef]

48. Amin, M.A.; El-Aasser, M.M.; Ayoub, S.M.; Shiek, H.E.H.; Sakr, T.M. Exploitation of Aspergillus flavus synthesized copper oxide nanoparticles as a novel medical agent. J. Radioanal. Nucl. Chem. 2021, 328, 299–313. [CrossRef]
49. Korany, M.; Marzook, F.; Mahmoud, B.; Ahmed, S.A.; Ayoub, S.M.; Sakr, T.M. Exhibiting the diagnostic face of selenium nanoparticles as a radio-platform for tumor imaging. Bioorg. Chem. 2020, 100, 103910. [CrossRef]

50. Korany, M.; Mahmoud, B.; Ayoub, S.M.; Sakr, T.M.; Ahmed, S.A. Synthesis and radiolabeling of vitamin C-stabilized selenium nanoparticles as a promising approach in diagnosis of solid tumors. J. Radioanal. Nucl. Chem. 2020, 325, 237–244. [CrossRef]

51. Swidan, M.M.; Khowsessah, O.M.; Abd El-Motaleb, M.; Abd El-Bary, A.; El-Kolyal, M.T.; Sakr, T.M. Iron oxide nanoparticulate system as a cornerstone in the effective delivery of Tc-99m radionuclide: A potential molecular imaging probe for tumor diagnosis. DARU J. Pharm. Sci. 2019, 27, 49–58. [CrossRef]

52. Sakr, T.M.; Khowsessah, O.; Motaleb, M.; Abd El-Bary, A.; El-Kolyal, M.; Swidan, M.M. I-131 doping of silver nanoparticles platform for tumor theranosis guided drug delivery. Eur. J. Pharm. Sci. 2018, 122, 239–245. [CrossRef][PubMed]

53. Mollarazi, E.; Jalilian, A.R.; Johari-daha, F.; Atyabi, F. Development of Sm-153-folate-polyethyleneimine-conjugated chitosan nanoparticles for targeted therapy. J. Label. Compd. Radiopharm. 2015, 58, 327–335. [CrossRef][PubMed]

54. Trujillo-Nolasco, R.M.; Morales-Avila, E.; Ocampo-Garcia, B.E.; Ferro-Flores, G.; Gibbens-Bandala, B.V.; Escudero-Castellanos, A.; Isaac-Olive, K. Preparation and in vitro evaluation of radiolabeled HA-PLGA nanoparticles as novel MTX delivery system for local treatment of rheumatoid arthritis. Mater. Sci. Eng. C Mater. Biol. Appl. 2019, 103, 109766. [CrossRef][PubMed]

55. Mendoza-Nava, H.; Ferro-Flores, G.; Ramirez, F.D.; Ocampo-Garcia, B.; Santos-Cuevas, C.; Aranda-Lara, L.; Azorin-Vega, E.; Morales-Avila, E.; Isaac-Olive, K. Lu-177-Dendrimer Conjugated to Folate and Bombesin with Gold Nanoparticles in the Dendritic Cavity: A Potential Theranostic Radiopharmaceutical. J. Nanomater. 2016, 2016, 1039258. [CrossRef]

56. Aranda-Lara, L.; Ocampo-Garcia, B.; Isaac-Olivé, K.; Ferro-Flores, G.; Meléndez-Alafort, L.; Morales-Avila, E. Drug Delivery Systems-Based Dendrimers and Polymer Micelles for Nuclear Diagnosis and Therapy. Macromol. Biosci. 2021, 21, 2000362. [CrossRef]

57. Al-Yasiri, A.Y.; White, N.E.; Katti, K.V.; Loyalka, S.K. Estimation of tumor and local tissue dose in gold nanoparticles radiotherapy for prostate cancer. Repr. Pract. Oncol. Radiother. 2019, 24, 288–293. [CrossRef]

58. Santos, J.J.; Leal, J.; Dias, L.A.P.; Toma, S.H.; Genezini, F.A.; Katti, K.V.; Araki, K.; Lugao, A.B. Bovine Serum Albumin Conjugated Gold-198 Nanoparticles as Model To Evaluate Damage Caused by Ionizing Radiation to Biomolecules. ACS Appl. Nano Mater. 2018, 1, 5062–5070. [CrossRef]

59. Iram, F.; Ishqal, M.S.; Khan, I.U.; Rasheed, R.; Khalid, A.; Khalid, M.; Aftab, S.; Shakoori, A.R. Synthesis and Biodistribution Study of Biocompatible Au-198 Nanoparticles by use of Arabinoxylan as Reducing and Stabilizing Agent. Biol. Trace Elem. Res. 2020, 193, 282–293. [CrossRef]

60. El-Safoury, D.; Ibrahim, A.B.; El-Setouhy, D.; Khowsessah, O.; Motaleb, M.; Sakr, T.M. Amelioration of Tumor Targeting and In Vivo Biodistribution of 99mTc-Methotrexate-Gold Nanoparticles (99mTc-Mex-AuNPs). J. Pharm. Sci. 2021, 110, 2955–2965. [CrossRef]

61. Jaime-Aguirre, L.; Morales-Avila, E.; Ocampo-Garcia, B.E.; Medina, L.A.; López-Téllez, G.; Gibbens-Bandala, B.V.; Izquierdo-Sánchez, V. Biodegradable poly (D, L-lactide-co-glycolide)/poly (L-glutamic acid) nanoparticles conjugated to folic acid for targeted delivery of doxorubicin. Mater. Sci. Eng. C Mater. Biol. Appl. 2017, 76, 743–751. [CrossRef]

62. Gibbens-Bandala, B.V.; Ocampo-Garcia, B.E.; Ferro-Flores, G.; Morales-Avila, E.; Ancira-Cortez, A.; Jaime-Aguirre, L. Multimetric System of RGD-Grafted PMMA-Nanoparticles as a Targeted Drug-Delivery System for Paclitaxel. Curr. Pharm. Des. 2017, 23, 3415–3422. [PubMed]

63. Abbas, A.; Khojasteh, H.; Hamadanian, M.; Salavati-Niasari, M. Synthesis of CoFe2O4 nanoparticles and investigation of the temperature, surfactant, capping agent and time effects on the size and magnetic properties. J. Mater. Sci. Mater. 2016, 27, 4972–4980. [CrossRef]

64. Feynman, R. There is plenty of room at the bottom. California Institute of Technology. Int. J. Eng. Sci. 1960, 4, 23–36.

65. Singh, A.; Gautam, P.K.; Verma, A.; Singh, V.; Shivapriya, P.M.; Shivalkar, S.; Sahoo, A.K.; Samanta, S.K. Green synthesis of metallic nanoparticles as effective alternatives to treat antibiotics resistant bacterial infections: A review. Biotechnol. Rep. 2020, 25, e00427. [CrossRef]

66. Xue, Z.; Zhang, Y.; Yu, W.; Zhang, J.; Wang, J.; Wan, F.; Kim, Y.; Liu, Y.; Kou, X. Recent advances in aflatoxin B1 detection based on nanotechnology and nanomaterials—A review. Anal. Chim. Acta 2019, 1069, 1–27. [CrossRef][PubMed]

67. Iravani, S.; Varma, R.S. Greener synthesis of lignin nanoparticles and their applications. Green Chem. 2020, 22, 612–636. [CrossRef]

68. Khoshneviasan, K.; Maleki, H.; Honavarvarfard, E.; Baharifar, H.; Gholami, M.; Faridbod, F.; Larijani, B.; Majidi, R.F.; Khorramizadeh, M.R. Nanomaterial based electrochemical sensing of the biomarker serotonin: A comprehensive review. Mikrochim. Acta 2019, 186, 49. [CrossRef]

69. Shnoudeh, A.J.; Hamad, I.; Abdo, R.W.; Qadumii, L.; Jaber, A.Y.; Surchi, H.S.; Alkelany, S.Z. Synthesis, characterization, and applications of metal nanoparticles. In Biomaterials and Biocatalyzed Nanotechnology; Elsevier: Amsterdam, The Netherlands, 2019; pp. 527–612.

70. Yaqoob, A.A.; Ahmad, H.; Parveen, T.; Ahmad, A.; Oves, M.; Ismail, I.M.; Qari, H.A.; Umar, K.; Mohamad Ibrahim, M.N. Recent advances in metal decorated nanomaterials and their various biological applications: A review. Front. Chem. 2020, 8, 341. [CrossRef]

71. Yaqoob, A.A.; Parveen, T.; Umar, K.; Mohamad Ibrahim, M.N. Role of nanomaterials in the treatment of wastewater: A review. Water 2020, 12, 495. [CrossRef]
99. Adamo, G.; Grimaldi, N.; Sabatino, M.A.; Walo, M.; Dispenza, C.; Ghersi, G. E-beam crosslinked nanogels conjugated with monoclonal antibodies in targeting strategies. *Biol. Chem.* 2017, 398, 277–287. [CrossRef]

100. Dispenza, C.; Sabatino, M.; Ajovalasit, A.; Ditta, L.; Ragusa, M.; Purrello, M.; Costa, V.; Conigliaro, A.; Alessandro, R. Nanogel-antiimiR-31 conjugates affect colon cancer cells behaviour. *RSC Adv.* 2017, 7, 52039–52047. [CrossRef]

101. Wongkrongsak, S.; Tangthong, T.; Pasanphan, W. Electron beam induced water-soluble silk fibroin nanoparticles as a natural antioxidant and reducing agent for a green synthesis of gold nanocolloid. *Radiat. Phys. Chem.* 2016, 118, 27–34. [CrossRef]

102. Rattanawongwiboon, T.; Haema, K.; Pasanphan, W. Stearyl methacrylate-grafted-chitosan nanoparticle as a nanofiller for PLA: Radiation-induced grafting and characterization. *Radiat. Phys. Chem.* 2014, 94, 205–210. [CrossRef]

103. Tangthong, T.; Piroonpan, T.; Thipe, V.C.; Khoobchandani, M.; Katti, K.; Katti, K.V.; Pasanphan, W. Bombesin Peptide Conjugated Water-Soluble Chitosan Gallate—A New Nanopharmaceutical Architecture for the Rapid One-Pot Synthesis of Prostate Tumor Targeted Gold Nanoparticles. *Int. J. Nanomed.* 2021, 16, 6957. [CrossRef]

104. Khoobchandani, M.; Katti, K.K.; Karikachery, A.R.; Thipe, V.C.; Sririmal, D.; Mohandoss, D.K.D.; Darshakumar, R.D.; Joshi, C.M.; Katti, K.V. New approaches in breast cancer therapy through green nanotechnology and nano-ayurvedic medicine–pre-clinical and pilot human clinical investigations. *Int. J. Nanomed.*, 2020, 15, 181. [CrossRef] [PubMed]

105. Khoobchandani, M.; Khan, A.; Katti, K.K.; Thipe, V.C.; Al-Yasiri, A.Y.; MohanDoss, D.K.; Nicholl, M.B.; Lugão, A.B.; Hans, C.P.; Katti, K.V. Green nanotechnology of MGF-AuNPs for immunomodulatory intervention in prostate cancer therapy. *Sci. Rep.* 2021, 11, 16797. [CrossRef] [PubMed]